Skip to content
POM-V Prescription Required Companion Animal

Zelys 5 mg Chewable Tablets for Dogs

Active ingredient: Pimobendan

Form

Chewable

Species

Dogs

Manufacturer

Ceva Sante Animale

VMD MA No.

14966/5086

What it's used for

See also section 3.9. AN: 02320/2025Page 2 of 6

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Pimobendan

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Zelys 5 mg Chewable Tablets for Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

See also section 3.9.
AN: 02320/2025Page 2 of 6
Do not exceed the recommended dosage.
To ensure a correct dosage, body weight should be determined as accurately as
possible.The tablets should be administered at a dose range of 0.2 mg to 0.6 mg
pimobendan/kg body weight per day. The preferable daily dose is 0.5 mg
pimobendan/kg body weight. The dose should be divided into two administrations
(0.25 mg/kg body weight each), using a suitable combination of whole, or half of
AN: 02320/2025Page 4 of 6
tablets. One half of the dose in the morning and the other half approximately 12
hours later.
Each dose should be given approximately one hour before feeding. Spontaneous
intake by the animal or place the tablet directly in the mouth.
This corresponds to:
One 5 mg chewable tablet in the morning and one 5 mg chewable tablet in the
evening for a body weight of 20 kg.
Tablets (1.25, 5 and 10 mg tablet) are divisible in two equal parts. The veterinary
medicinal product may be combined with a diuretic treatment such as furosemide.
Do not use pimobendan in hypertrophic cardiomyopathies or in diseases in which an
improvement in cardiac output cannot be achieved for functional or anatomical
reasons (e.g. aortic stenosis).
Do not use in dogs with severe impairment of liver function since pimobendan is
metabolised mainly via the liver.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients (See also section 3.7).
Dogs:
Rare
(1 to 10 animals / 10,000
animals treated):
Vomiting
, Diarrhoea
,
Anorexia
, Lethargy
,
Increased heart rate
, Heart valve disorder
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Mucosa petechiae
, Haemorrhage
4,5
Dose-dependent and can be avoided by reducing the dose.
Transient
An increase in mitral valve regurgitation has been observed during chronic
pimobendan treatment in dogs with mitral valve disease.
Although a relationship with pimobendan has not been clearly established, these
signs of effects on primary haemostasis disappear when the treatment is withdrawn.
Subcutaneous
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.
None

Special precautions for safe use in the target species:
The blood glucose should be tested regularly during treatment in dogs with existing
diabetes mellitus.
Monitoring of cardiac function and morphology is recommended in animals treated
with pimobendan (See also section 3.6)
The chewable tablets are flavoured. In order to avoid any accidental ingestion, store
tablets out of reach of the animals.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Accidental ingestion, especially by a child, may lead to the occurrence of tachycardia,
orthostatic hypotension, flushing of the face and headaches.
Unused part-tablets should be returned to the open blister space, or to the bottle and
inserted back into the outer packaging. Keep in a safe place out of the sight and
reach of children.
Close bottle tightly with cap directly after removal of the required number of tablets or
part-tablets.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.
AN: 02320/2025Page 3 of 6
In pharmacological studies no interaction between the cardiac glycosides
strophanthin and pimobendan was observed. The pimobendan-induced increase in
cardiac contractility is attenuated by the calcium antagonists verapamil and diltiazem
and by the β-antagonist propranolol.
For blisters: Any unused tablet portion should be returned to the blister and be used
for the next administration.
Do not store above 30C.
For bottle: Keep the bottle tightly closed in order to protect from moisture.
Any unused tablet portion should be returned to the bottle and be used for the next
administration.
Do not store above 25C.
AN: 02320/2025Page 6 of 6
Not applicable

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.